Employees organization/structure and functioning of the stem cell transplant center – how to optimize the transplant program?
Abstract
The majority of patients presenting with peripheral lymphadenopathy have easily identifiable causes that are benign or self-limited. Among primary care patients presenting with lymphadenopathy, the prevalence of malignancy has been estimated to be as low as 1.1 %. The critical challenge for the primary care physician is to identify which cases are secondary to malignancies or other serious conditions. Key risk factors for malignancy include older age, firm, fixed nodal character, duration of greater than two weeks, and supraclavicular location. Knowledge of these risk factors is critical to determining the management of unexplained lymphadenopathy. In addition, a complete exposure history, review of associated symptoms, and a thorough regional examination help determine whether lymphadenopathy is of benign or malignant origin. Unexplained lymphadenopathy without signs or symptoms of serious disease or malignancy can be observed for one month, after which specific testing or biopsy should be performed. While modern hematopathologic technologies have improved the diagnostic yields of fine-needle aspiration, excisional biopsy remains the initial diagnostic procedure of choice.
References
Pravilnik o bližim uslovima za obavljanje zdravstvene delatnosti u zdravstvenim ustanovama i drugim oblicima zdravstvene službe („Službeni glasnik RS”, broj 107/05).
ISO9001:2015 Quality management systems – Requirements
ISO 13485:2016 Medical devices – QMS. https://www.iso.org/standard/59752.html
ISO. Medical laboratories -Particular requirements for quality and competence. ISO 15189:2007.
ISO/IEC 17025:2017. Best ISO 17025 quality manual. www.globalmanagergroup.com
ISO: General requirements for the competence of testing and calibration laboratories. ISO/IEC 17025:2005.
Nassar A, Srivastava A, Hashmi SK, Aljurf M. Establishing an HSCT Program with Limited Resources. In: Gluckman E, Niederwieser D, Aljur M, eds. Establishing a Hematopoietic Stem Cell Transplantation Unit. Springer; 2018. ISBN 978-3-319-59358-6 (eBook).
Thorsteinsdóttir H, Quach U, Martin DK, Daar AS, Singer PA. Introduction: promoting global health through biotechnology. Nat Biotechnol 2004; 22: 3-7.
Lee SJ. Outcomes research in hematopoietic cell transplantation. In: Appelbaum FR, Forman SJ, Negrin RS, Blime KG, eds. Thomas’ Hematopoietic Cell Transplantation. 4th ed. Chichester, UK: Wiley-Blackwell; 2004. p. 428-41.
Yu YB, Gau JP, You JY, Chern HH, Chau WK, Tzeng CH, Ho CH, Hsu HC. Cost-effectiveness of postremission intensive therapy in patients with acute leukemia. Ann Oncol 2006; 18(3): 529-34.
Imataki O, Kamioka T, Fukuda T, Tanosaki R, Takaue Y. Cost and effectiveness of reduced-intensity and conventional allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Support Care Cancer 2010; 18(12): 1565-9.
Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3. New York: Oxford University Press; 2005. p. 8-25. p. 38-48. p. 126-133.
World Health Organization. Basic Documents-48th Ed [Internet]. Geneva: WHO Press; 2014. http://apps.who.int/gb/bd
Stranges E, Russo CA, Friedman B. Procedures with the most rapidly increasing hospital costs, 2004–2007, HCUP Statistical Brief 82. Rockville: Agency for Healthcare Research and Quality. Dec 2009. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb82.pdf
Griffiths RI, Bass EB, Powe NR, Anderson GF, Goodman S, Wingard JR. Factors influencing third party payer costs for allogeneic BMT. Bone Marrow Transplant 1993; 12(1): 43-8.
Preussler JM, Denzen EM, Majhail NS. Costs and cost-effectiveness of hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18(11): 1620-8.
Majhail NS, Mothukuri JM, Macmillan ML, Verneris MR, Orchard PJ, Wagner JE, Weisdorf DJ. Costs of pediatric allogeneic hematopoietic-cell transplantation. Pediatr Blood Cancer 2010; 54(1): 138-43.
Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transplant 2009; 15(5): 564-73.
Saito AM, Zahrieh D, Cutler C, Ho VT, Antin JH, Soiffer RJ, Alyea EP, Lee SJ. Lower costs associated with hematopoietic cell transplantation using reduced-intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant 2007; 40(3): 209-17.
Rizzo JD, Vogelsang GB, Krumm S, Frink B, Mock V, Bass EB. Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting? J Clin Oncol 1999; 17(9): 2811-8.
